OPEN END TURBO LONG - BOSTON SCIENTIFIC | Delayed Börse Stuttgart 06:31:39 2024-06-17 am EDT | ||
| 3.73 EUR | +0.54% |
|
| Current month | +6.00% | ||
| 1 month | +9.44% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BOSTON SCIENTIFIC CORPORATION
| Date | Price | Change |
|---|---|---|
| 24-06-17 | 3.73 | +0.54% |
| 24-06-14 | 3.71 | +0.27% |
| 24-06-13 | 3.7 | -0.80% |
| 24-06-12 | 3.73 | +0.27% |
| 24-06-11 | 3.72 | -0.53% |
Delayed Quote Börse Stuttgart
Last update June 17, 2024 at 06:31 am EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | BOSTON SCIENTIFIC CORPORATION |
| Issuer | Morgan Stanley |
| WKN | MD59NN |
| ISIN | DE000MD59NN6 |
| Date issued | 2022-06-16 |
| Strike | 37.19 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.41 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.76 € |
|---|---|
| Lowest since issue | 0.41 € |
| Spread | 0.06 € |
| Spread % | 1.58% |
Company Profile
Boston Scientific Corporation specializes in the design, manufacturing and marketing of medical equipment and materials. Net sales break down by area of application as follows:
- cardiovascular (60.6%): products used in cardiology surgeries (27.4% of net sales), cardiac rhythm management (25.2%), peripheral surgeries (23.9%), electrophysiology tests (9.1%) and other (14.4%);
- endodontic surgery (37.4%): equipment used in endoscopy (45.8% of net sales), urology (36.2%) and other (18%) ;
- neuromodulation (2%).
The United States account for 59.2% of net sales.
Sector
-
Ratings for Boston Scientific Corporation
Trading Rating
Investor Rating
ESG Refinitiv
A-
Consensus: Boston Scientific Corporation
Sell
Buy
Mean consensus
BUY
Number of Analysts
32
Last Close Price
76.76
USD
Average target price
82.26
USD
Spread / Average Target
+7.16%
- Stock Market
- Certificates
- Certificat
